OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
11
Results
Show all
Save search
Copy query
Show results for
Unknown
(11)
Publication Date
Release Date
2022
(3)
2021
(3)
2024
(2)
2026
(1)
2020
(1)
2016
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort.
Not available
S-EPMC9874469
|
biostudies-literature
Cite
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).
Not available
S-EPMC7900694
|
biostudies-literature
Cite
TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B-Cell Lymphoma in the Real-Life Patient Journey.
Not available
S-EPMC12801173
|
biostudies-literature
Cite
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer.
Not available
S-EPMC8238951
|
biostudies-literature
Cite
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol.
Not available
S-EPMC9221405
|
biostudies-literature
Cite
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
Not available
S-EPMC8047485
|
biostudies-literature
Cite
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment.
Not available
S-EPMC11199338
|
biostudies-literature
Cite
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.
Not available
S-EPMC7649863
|
biostudies-literature
Cite
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.
Not available
S-EPMC11362642
|
biostudies-literature
Cite
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.
Not available
S-EPMC9349965
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets